Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK2 | P24941 | 6/20 | 0.55 |
| ▸ | CDK1 | P06493 | 3/20 | 0.55 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.48 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.48 |
| ▸ | JAK2 | O60674 | 2/20 | 0.47 |
| ▸ | JAK3 | P52333 | 2/20 | 0.47 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.47 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.47 |
| ▸ | NCOR1 | O75376 | 1/20 | 0.47 |
| ▸ | JAK1 | P23458 | 1/20 | 0.47 |
| ▸ | TYK2 | P29597 | 1/20 | 0.47 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.47 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.47 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.47 |
| ▸ | CDK4 | P11802 | 2/20 | 0.46 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.46 |
| ▸ | SYK | P43405 | 9/20 | 0.45 |
| ▸ | CAMK2D | Q13557 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL700913 | 0.88 | CDK2 (0.51) | CDK2CDK1MKNK1MKNK2JAK2 | |
| SCHEMBL700602 | 0.87 | HDAC1 (0.60) | CDK2CDK1JAK2HDAC1HDAC3 | |
| SCHEMBL699658 | 0.84 | HDAC1 (0.58) | CDK2CDK1JAK2JAK3HDAC1 | |
| SCHEMBL3540121 | 0.83 | CDK2 (0.66) | CDK2CDK1HDAC1CDK4CCNE1 | |
| SCHEMBL699357 | 0.83 | CDK2 (0.60) | CDK2CDK1JAK2JAK3HDAC1 | |
| SCHEMBL658769 | 0.83 | MKNK1 (0.46) | CDK2CDK1MKNK1MKNK2HDAC1 | |
| SCHEMBL700146 | 0.81 | CDK2 (0.49) | CDK2CDK1JAK2JAK3HDAC1 | |
| SCHEMBL700145 | 0.81 | CDK2 (0.49) | CDK2CDK1JAK2JAK3HDAC1 | |
| SCHEMBL3611097 | 0.81 | CDK2 (0.61) | CDK2CDK1HDAC1CDK4CCNE1 | |
| SCHEMBL700078 | 0.80 | AURKA (0.53) | CDK2JAK2JAK3HDAC1HDAC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8124764-B2 | Fused heterocyclyc inhibitor compounds | GILEAD SCIENCES, INC. (US) | 2012-02-28 | — | — | US | claimed |
| US-20100029638-A1 | FUSED HETEROCYCLYC INHIBITOR COMPOUNDS | GILEAD SCIENCES, INC. | 2010-02-04 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100029638-A1 | FUSED HETEROCYCLYC INHIBITOR COMPOUNDS | HDAC1, HDAC11, HDAC7 | CDK2 16/4885CDK1 13/4885MKNK1 119/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.